PRECISION BIOSCIENCES INC
DTILNasdaq
$7.87
↓ -5.4%Jul 17 close · end-of-day
Price
1Y↑ +74.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$193.9M
Enterprise Value
$92.7M
P/E
—
P/S
4.3
P/B
2.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$45.1M
Net Income (TTM)
-$43.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-86.8%
Net Margin
-96.7%
ROE
-57.3%
ROIC
—
Debt / Equity
—
Net Cash
$101.2M
Return 1Y
+69.6%
Company profile
Precision BioSciences offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells. PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL.
- CEO
- Michael Amoroso
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Headquarters
- North Carolina
- Website
- precisionbiosciences.com
Management & directors
- Amoroso MichaelPresident and CEO
- Kelly John AlexanderChief Financial Officer
- Smith J. JeffersonChief Research Officer
- Scimeca DarioGeneral Counsel and Secretary
Roles derived from SEC Form 4 filings.
Earnings
DTIL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.8M↑ +37272.4%
Diluted EPS-$0.75↓ -66.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$109.8M | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M |
| Net income | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| Diluted EPS | — | -$0.52 | -$38.10 | -$15.96 | $1.04 | -$3.56 |
| Operating cash flow | -$87.4M | -$10.9M | -$45.8M | -$84.1M | -$58.4M | -$65.8M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -452.2% | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Net margin | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.9M | $576,000.00 | $638,000.00 | $29,000.00 | $18,000.00 | $13,000.00 | $34.2M | $10.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $24.1M | -$21.3M | -$24.8M | -$22.1M | -$21.9M | -$20.7M | $12.5M | -$9.1M |
| Net income | $32.7M | -$16.4M | -$17.7M | -$20.6M | -$23.5M | -$21.8M | $20.1M | -$18.4M |
| Diluted EPS | $4.67 | -$2.25 | -$3.08 | -$2.21 | -$2.13 | -$1.84 | $2.62 | -$0.75 |
| Operating cash flow | -$14.9M | -$5.9M | -$18.7M | -$19.1M | -$20.3M | -$15.3M | -$11.3M | -$11.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 48.4% | -3693.6% | -3894.4% | -76248.3% | -121538.9% | -158976.9% | 36.6% | -83.7% |
| Net margin | 65.6% | -2851.6% | -2781.3% | -70913.8% | -130666.7% | -167476.9% | 58.9% | -170.2% |
Company news
May 21, 2026
- 60d ago[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)finance.yahoo.com
- 60d agoPrecision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Buehler Kevin | Option exercise | 21,000 | — | — | filing |
| 2026-05-20 | Frankel Stanley | Option exercise | 21,000 | — | — | filing |
| 2026-05-20 | Brown Melinda | Option exercise | 21,000 | — | — | filing |
| 2026-05-20 | Pire Shari Lisa | Option exercise | 21,000 | — | — | filing |
| 2026-05-20 | Germano Geno J | Option exercise | 21,000 | — | — | filing |
| 2026-02-18 | Amoroso Michael· President and CEO | Sale | 20,559 | $3.84 | $78,946.56 | filing |
| 2026-02-18 | Kelly John Alexander· Chief Financial Officer | Sale | 8,149 | $3.84 | $31,292.16 | filing |
| 2026-02-18 | Scimeca Dario· General Counsel and Secretary | Sale | 4,925 | $3.84 | $18,912.00 | filing |
| 2026-02-18 | SMITH J. JEFFERSON· Chief Research Officer | Sale | 4,925 | $3.84 | $18,912.00 | filing |
| 2026-02-17 | Amoroso Michael· President and CEO | Option exercise | 67,797 | $0.00 | $0.00 | filing |
| 2026-02-17 | Kelly John Alexander· Chief Financial Officer | Option exercise | 27,584 | $0.00 | $0.00 | filing |
| 2026-02-17 | Scimeca Dario· General Counsel and Secretary | Option exercise | 16,667 | $0.00 | $0.00 | filing |
| 2026-02-17 | SMITH J. JEFFERSON· Chief Research Officer | Option exercise | 16,667 | $0.00 | $0.00 | filing |
| 2026-01-22 | Amoroso Michael· President and CEO | Sale | 34,799 | $4.17 | $145,111.83 | filing |
| 2026-01-21 | Kelly John Alexander· Chief Financial Officer | Sale | 15,213 | $4.03 | $61,308.39 | filing |
| 2026-01-21 | SMITH J. JEFFERSON· Chief Research Officer | Sale | 10,200 | $4.03 | $41,106.00 | filing |
| 2026-01-21 | Scimeca Dario· General Counsel and Secretary | Sale | 8,854 | $4.03 | $35,681.62 | filing |
| 2026-01-21 | SMITH J. JEFFERSON· Chief Research Officer | Option exercise | 16,219 | — | — | filing |
| 2026-01-20 | Scimeca Dario· General Counsel and Secretary | Option exercise | 14,908 | $0.00 | $0.00 | filing |
| 2026-01-20 | Scimeca Dario· General Counsel and Secretary | Option exercise | 1,978 | $0.00 | $0.00 | filing |
| 2026-01-20 | Scimeca Dario· General Counsel and Secretary | Option exercise | 8,425 | $0.00 | $0.00 | filing |
| 2026-01-20 | SMITH J. JEFFERSON· Chief Research Officer | Option exercise | 2,500 | — | — | filing |
| 2026-01-20 | SMITH J. JEFFERSON· Chief Research Officer | Option exercise | 10,447 | — | — | filing |
| 2026-01-20 | Amoroso Michael· President and CEO | Option exercise | 8,888 | — | — | filing |
| 2026-01-20 | Kelly John Alexander· Chief Financial Officer | Option exercise | 3,888 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.